{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T08:27:55Z","timestamp":1786523275392,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"publisher","award":["6-2024-0191"],"award-info":[{"award-number":["6-2024-0191"]}],"id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijrobp.2026.03.012","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:41:37Z","timestamp":1773852097000},"page":"167-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patterns of Progression After First-Line Systemic Therapy in Metastatic Breast Cancer and the Potential of ctDNA to Guide Metastasis-Directed Therapy: Implications for Breast Oligometastases Management"],"prefix":"10.1016","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7685-3382","authenticated-orcid":false,"given":"Jee Suk","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joohyuk","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gun Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2026.03.012_bib0001","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.012_bib0002","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.012_bib0003","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/COC.0000000000000169","article-title":"Definitive stereotactic body radiotherapy (SBRT) for extracranial oligometastases: An international survey of >1000 radiation oncologists","volume":"40","author":"Lewis","year":"2017","journal-title":"Am J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ijrobp.2026.03.012_bib0004","article-title":"NRG-BR002: A phase IIR\/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and\/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557)","volume":"40","author":"Chmura","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.012_bib0005","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"Tsai","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2026.03.012_bib0006","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ijrobp.2024.10.030","article-title":"Adding metastasis-directed therapy to standard-of-care systemic therapy for oligometastatic breast cancer (EXTEND): A multicenter, randomized phase 2 trial","volume":"121","author":"Reddy","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.03.012_bib0007","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/PPO.0000000000000202","article-title":"Stereotactic body radiotherapy for oligometastasis: Opportunities for biology to guide clinical management","volume":"22","author":"Correa","year":"2016","journal-title":"Cancer J"},{"key":"10.1016\/j.ijrobp.2026.03.012_bib0008","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1097\/JTO.0000000000000648","article-title":"Pattern of failure analysis in metastatic EGFR-mutant lung cancer treated with tyrosine kinase inhibitors to identify candidates for consolidation stereotactic body radiation therapy","volume":"10","author":"Al-Halabi","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.012_bib0009","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/17407745211066498","article-title":"A short history of Bernard Fisher's contributions to randomized clinical trials","volume":"19","author":"Anderson","year":"2022","journal-title":"Clin Trials"},{"key":"10.1016\/j.ijrobp.2026.03.012_bib0010","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/PPO.0000000000000437","article-title":"Circulating tumor DNA biomarkers for early detection of oligometastasis","volume":"26","author":"Routman","year":"2020","journal-title":"Cancer J"},{"key":"10.1016\/j.ijrobp.2026.03.012_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110364","article-title":"Longitudinal cell-free DNA characterization by low-coverage whole-genome sequencing in patients undergoing high-dose radiotherapy","volume":"197","author":"Bal\u00e1zs","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.012_bib0012","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/jnci\/djad080","article-title":"Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancer","volume":"115","author":"Kim","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2026.03.012_bib0013","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1080\/02841860802662722","article-title":"Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis","volume":"48","author":"Rusthoven","year":"2009","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.012_bib0014","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.3390\/cancers16132407","article-title":"Circulating tumor DNA predicts early recurrence following locoregional therapy for oligometastatic colorectal cancer","volume":"16","author":"O\u2019Donnell","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ijrobp.2026.03.012_bib0015","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41698-023-00440-6","article-title":"Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancer","volume":"7","author":"Semenkovich","year":"2023","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.012_bib0016","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ijrobp.2019.10.038","article-title":"Immune and circulating tumor DNA profiling after radiation treatment for oligometastatic non-small cell lung cancer: Translational correlatives from a mature randomized phase II trial","volume":"106","author":"Tang","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.03.012_bib0017","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1038\/s41598-025-88266-z","article-title":"Long-term survival and undetectable circulating tumor DNA following comprehensive involved site radiotherapy for oligometastases","volume":"15","author":"Radigan","year":"2025","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.ijrobp.2026.03.012_bib0018","doi-asserted-by":"crossref","DOI":"10.1200\/OA-25-00031","article-title":"Stereotactic ablative body radiotherapy for oligoprogressive estrogen receptor\u2013positive breast cancer (TROG 20.03 AVATAR): A phase II prospective multicenter trial","author":"David","year":"2025","journal-title":"JCO Oncol Adv"},{"key":"10.1016\/j.ijrobp.2026.03.012_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218106","article-title":"Rethinking clinical trial endpoints for evaluating serially delivered 'strategic radiotherapy' in oligometastatic or oligoprogressive metastatic disease","volume":"635","author":"Chang","year":"2025","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ijrobp.2026.03.012_bib0020","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijrobp.2024.08.031","article-title":"Stereotactic ablative radiation for oligoprogressive cancers: Results of the randomized phase 2 STOP trial","volume":"121","author":"Schellenberg","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.03.012_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115737","article-title":"Multinational validation of distant metastasis velocity as a post-progression prognostic score in patients with oligometastatic cancer treated with metastasis-directed stereotactic body radiotherapy","volume":"228","author":"Willmann","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2026.03.012_bib0022","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2026.03.012_bib0023","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2026.03.012_bib0024","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2501796","article-title":"Overall survival with inavolisib in PIK3CA-mutated advanced breast cancer","volume":"393","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626004979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626004979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:36:20Z","timestamp":1786520180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301626004979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0360301626004979"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.03.012","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of Progression After First-Line Systemic Therapy in Metastatic Breast Cancer and the Potential of ctDNA to Guide Metastasis-Directed Therapy: Implications for Breast Oligometastases Management","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}